|
|
|
| Clinical Efficacy of Ganciclovir in the Treatment of Cytomegalovirus Hepatitis in Children |
| GUO Hui-min, ZHANG Yan-xiang, SONG Jian-gang |
| Department of Pediatrics Baota District People's Hospital,Yan'an Shaanxi 716000 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy of ganciclovir in the treatment of cytomegalovirus (CMV) hepatitis in children. 【Methods】 The clinical data of 88 children with cytomegalovirus hepatitis admitted to our hospital from March 2019 to March 2021 were analyzed retrospectively. They were divided into observation group and control group according to different antiviral drugs, with 44 cases in each group. The children in the control group were treated with reduced glutathione, and the children in the observation group were treated with ganciclovir on the basis of the control group. The jaundice regression time, liver retraction time, spleen retraction time, the level serum total bilirubin (TBIL), alanine aminotransferase (ALT), γ- glutamyltranspeptidase (GGT) before and after the therapy and the clinical efficacy and adverse reactions of the two groups were compared.【Results】 The time of jaundice regression, liver retraction and spleen retraction in the observation group was significantly lower than that in the control group (P<0.05). After treatment, the levels of serum TBIL, ALT and GGT in the two groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05). The total clinical effective rate in the observation group was 93.18% (41/44), higher than that in the control group [77.27% (34/44)], with a statistically significant difference(χ2=4.423,P=0.036). There was no significant difference in the incidence of adverse reactions between the two groups(χ2=1.048,P=0.310).【Conclusion】 Ganciclovir antiviral therapy can shorten the time of clinical symptom disappearance, promote the recovery of liver function, and it is safe and reliable.
|
|
Received: 26 August 2022
|
|
|
|
|
|
[1] FOWLER K B,BOPPANA S B. Congenital cytomegalovirus infection[J].Semin Perinatol,2018,42(3):149-154.
[2] NICLOUX M,PETERMAN L,PARODI M,et al. Outcome and management of newborns with congenital cytomegalovirus infection[J].Arch Pediatr,2020,27(3):160-165.
[3] 窦冬冬,张楠,潘峰. 先天性人巨细胞病毒感染对肝脏的损伤作用及相关血清标志物的分析[J].肝脏,2019,24(10):1161-1163.
[4] 董雪婷,杨辉,吴艳玲,等. 脾氨肽联合还原型谷胱甘肽改善巨细胞病毒肝炎患儿肝功能损害及免疫功能的临床疗效[J].临床与病理杂志,2019,39(8):1654-1660.
[5] 罗明海,张森山. 更昔洛韦联合双歧杆菌三联活菌治疗小儿巨细胞病毒感染性肝炎的有效性和安全性分析[J].肝脏,2019,24(4):118-120.
[6] 王维. 利可君片联合更昔洛韦治疗巨细胞病毒性肝炎婴儿的效果分析[J].实用临床医药杂志,2019,23(1):115-117.
[7] BARTON M,FORRESTER A M,MCDONALD J. Update on congenital cytomegalovirus infection:Prenatal prevention,newborn diagnosis and management[J].Paediatr Child Health,2020,25(6):395-396.
[8] 肖红利,查琳,邓敏,等. 婴幼儿期巨细胞病毒肝炎患儿的细胞因子水平检测[J].临床检验杂志(电子版),2019,8(1):62-63.
[9] 唐莹莹,梅红,刘花,等. 腺苷蛋氨酸与熊去氧胆酸联合治疗巨细胞病毒感染相关婴儿肝炎综合征的效果[J].中华医院感染学杂志,2019,29(23):3661-3665.
[10] 王锡兰,田军. CMV感染性肝炎患儿外周血T淋巴细胞的水平及意义[J].中国妇幼健康研究,2019,30(1):65-68.
[11] MOZAFFAR M,SHAHIDI S,MANSOURIAN M,et al. Optimal use of ganciclovir and valganciclovir in transplanted patients:how does it relate to the outcome?[J].J Transplant,2018,18(8):841-848.
[12] 谭细妹,杨斌,祁云,等.还原型谷胱甘肽联合更昔洛韦对巨细胞病毒肝炎患儿肝功能CMV DNA和T细胞亚群的影响[J].河北医学,2022,28(6):1024-1028.
[13] KRONIG I,ELKRIEF L,BERNEY T,et al. Combination treatment with letermovir and ganciclovir for maintenance therapy of multidrug-resistant CMV infection in a liver transplant recipient[J].Transplantation,2020,104(8):248-249.
[14] 吴春美,辛毅. 更昔洛韦联合腺苷蛋氨酸治疗婴儿巨细胞病毒性肝炎对IL-8、INF-γ、vWF及D-D水平的影响[J].肝脏,2019,24(7):3-9. |
|
|
|
2022, Vol. 39 
